Group 1 - Shandong Luzhong Investment Co., Ltd. plans to issue a second phase of medium-term notes for 2025, with a dynamic adjustment mechanism for the issuance amount, a base amount of 0 billion, and a maximum issuance amount of 3.5 billion, with a term of 3 years [1] - The funds raised will be used entirely to repay financial institution borrowings, with a total outstanding direct debt of 4.265 billion as of the date of the prospectus, including 500 million in MTN bonds, 2.1 billion in PPN bonds, 1.48 billion in corporate bonds, and 185 million in overseas debt [1] - Luzhong Investment is a wholly-owned subsidiary of Shandong Luzhong Holding Group Co., Ltd., established in July 2016, with a registered capital of 300 million [2] Group 2 - In June 2023, China National Pharmaceutical Group Corporation and its subsidiaries signed an investment cooperation agreement with Luzhong Holding and Luzhong Investment, agreeing to jointly increase capital by 2.449 billion to acquire a 51% stake in Luzhong Investment, which will result in a change of controlling shareholder to China National Pharmaceutical Group [4][5] - The investment cooperation agreement has not yet taken effect, but has received necessary approvals from regulatory authorities [4] - Luzhong Investment's core business is pharmaceutical glass bottles, which accounted for 90.83% to 99.43% of its revenue from 2022 to the first nine months of 2025, while its energy business contributed a much smaller proportion [5][6] Group 3 - Luzhong Investment's other income has been decreasing over the years, with government subsidies significantly impacting net profit, indicating potential vulnerability to changes in government subsidy policies [6] - The company aims to expand its operational scale and enhance economic efficiency in the coming years, supported by local government initiatives, while diversifying its investment and development strategies [6]

Investment Rating - The report maintains a "Strong Buy" rating for Shandong Pharmaceutical Glass [2][6] Core Views - The company reported a revenue of 3.401 billion yuan for the first three quarters of 2025, a year-on-year decrease of 11.10%, and a net profit attributable to shareholders of 542 million yuan, down 24.70% year-on-year [3][4] - The decline in revenue and profit is attributed to weak industry demand, particularly due to the implementation of the 10th batch of national drug procurement starting in April 2025, which is expected to affect the demand for borosilicate molded bottles until December 2027 [4] - The company has improved its gross margin to 33.08%, an increase of 0.98 percentage points year-on-year, due to a higher proportion of high-end products [4] - The change in the controlling shareholder to China National Pharmaceutical Group is expected to provide new resources for the company's development, enhancing its market position and R&D capabilities [5] Summary by Sections Financial Performance - For the first three quarters of 2025, the company achieved a basic EPS of 0.82 yuan, with a net profit margin of 15.95%, down 2.89 percentage points year-on-year [3][4] - The management expense ratio increased to 5.71%, up 1.88 percentage points year-on-year, primarily due to rising employee compensation and depreciation [4] - The R&D expense ratio rose to 4.07%, an increase of 1.05 percentage points year-on-year, reflecting higher R&D personnel costs [4] Production Capacity and Market Position - The company is expanding its production capacity with a new project for 4 billion borosilicate molded bottles, which is expected to enhance its scale and competitive advantage [5] - The company’s production capacity is sufficient to meet customer demand, and once market demand recovers, it is anticipated to lead to significant performance elasticity [5] Profit Forecast - The forecast for net profit attributable to shareholders for 2025-2027 is 743 million, 885 million, and 1.029 billion yuan, respectively, with corresponding EPS of 1.12, 1.33, and 1.55 yuan [6]